S100鈣結(jié)合蛋白A7(S100A7)單克隆抗體
Monoclonal Antibody to S100 Calcium Binding Protein A7 (S100A7)
S100-A7; PSOR1; S100A7c; Psoriasin 1
- 編號MAC035Hu22
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)-
- Ig亞型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 -
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有0.02% NaN3和50%甘油)
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù),請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 666 ¥ 1554 ¥ 2220 ¥ 5550 ¥ 22200
- 欲了解實(shí)際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對S100A7的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識別S100A7。
用法
免疫印跡:0.2-2μg/mL;1:500-5000
免疫組織化學(xué):5-20μg/mL;1:50-200
免疫細(xì)胞化學(xué):5-20μg/mL;1:50-200
最佳稀釋倍數(shù)最終由用戶決定。
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長臂生物素標(biāo)記試劑盒
實(shí)時熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPC035Hu01 | S100鈣結(jié)合蛋白A7(S100A7)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APC035Hu01 | S100鈣結(jié)合蛋白A7(S100A7)活性蛋白 | Cell?culture;?Activity?Assays. |
PAC035Hu01 | S100鈣結(jié)合蛋白A7(S100A7)多克隆抗體 | WB |
LAC035Hu71 | S100鈣結(jié)合蛋白A7(S100A7)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAC035Hu22 | S100鈣結(jié)合蛋白A7(S100A7)單克隆抗體 | WB; IHC; ICC; IP. |
SEC035Hu | S100鈣結(jié)合蛋白A7(S100A7)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMC035Hu | S100鈣結(jié)合蛋白A7(S100A7)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Archives of Dermatological Research | Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters [SpringerLink: t07u24t43r357l15] |
J Proteome Res | Proteomic Signature of Endothelial Dysfunction Identified in the Serum of Acute Ischemic Stroke Patients by the iTRAQ-Based LC–MS Approach [PubMed: 25807139] |
Exp Dermatol | S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretion through IκB/NF-κB signaling [Pubmed:27060579] |
Experimental Dermatology | S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL‐6 secretion through IκB/NF‐κB signalling [pubmed:27060579] |
Experiental And Therapeutic Medicine | Plasma proteins as potential targets of abnormal Savda syndrome in asthma patients treated with unique Uighur prescription [pubmed:28672924] |
Scientific Reports | The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. [pubmed:29142248] |
Journal of the European Academy of Dermatology and Venereology | A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis [Pubmed:28681537] |
Scientific Reports | Measurements of AMPs in stratum corneum of atopic dermatitis and healthy skin–tape stripping technique [Pubmed:29374283] |
Neuroscience?Bulletin | Comprehensive proteomic profiling of patients' tears identifies potential biomarkers for the traumatic vegetative state [Pubmed:30019218] |
Journal of Proteomics | Salivary proteins from dysplastic leukoplakia and oral squamous cell carcinoma and their potential for early detection [Pubmed: 31706945] |
Mediators of Inflammation | Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris [] |